As the European equine health specialist, Audevard is committed to advancing veterinary care with practical and effective solutions.
Their growing portfolio highlights our dedication to providing veterinarians with innovative solutions to deliver optimal care for all horses: Equioxx (only firocoxib in tablet form for horses), Tildren (only tiludronate in veterinary medicine), Ekyflogyl (only topical corticosteroid gel for horses) and Imaverol (only topical multispecies medicine against ringworm).
Today, Audevard is proud to announce the launch of new product: Prasequine (pergolide 1mg), a quarter-scored tablet format for precise management of Equine Cushing’s disease (PPID). Prasequine is now available from your veterinary wholesaler.
Prasequine’s quarter-scored tablet format offers an advantage for veterinarians and horse owners. This design ensures precise dose adjustments, enabling tailored treatments that meet the unique needs of every PPID horse.
The quarter-scored tablet makes it easier to administer the exact amount of pergolide required, simplifying prescription and enhancing treatment outcomes. Prasequine composition is identical to that of the original drug and tablets can be stored for up to 3 days after being split.
Prasequine is available in 2 sizes: 60 tablets and 160 tablets boxes to meet the need of every horse owner.
“Veterinarians need precision and reliability when managing complex conditions like PPID. With Prasequine, we’re offering a medicine that combines precision, practicality, and Audevard’s trusted expertise in equine health.” says Dr Vincent Chassaing, scientific and marketing director for Audevard.
